Lannett Company (NYSE:LCI) has entered
into an exclusive U.S. distribution agreement for the therapeutically
equivalent generic of ADVAIR DISKUS (Fluticasone Propionate – Salmeterol
Xinafoate Powder Inhaler) of Respirent Pharmaceuticals.
Under the agreement, Lannett will make an upfront
payment, as well as future milestone payments, and receive a portion of
the net profits once it commences distribution.
The term of the agreement is 10 years. Other terms were not disclosed.
ADVAIR DISKUS is a registered trademark of
GlaxoSmithKline. It had U.S. sales of $3.6B for the 12 months ending
July, 2019, according to IQVIA.
https://seekingalpha.com/news/3502818-lannett-inks-deal-generic-advair-diskus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.